Safety, efficacy and acceptability of SARS-CoV-2 vaccines in patients with cancer.
作者信息
Chebel Roy, Labaki Chris, Farhat Maria, Kattan Joseph
机构信息
Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Saint Joseph University, Beirut, Lebanon.
出版信息
Future Virol. 2021 Jun. doi: 10.2217/fvl-2021-0072. Epub 2021 Jun 30.
Abstract
摘要
相似文献
1
Safety, efficacy and acceptability of SARS-CoV-2 vaccines in patients with cancer.SARS-CoV-2疫苗在癌症患者中的安全性、有效性和可接受性。
Future Virol. 2021 Jun. doi: 10.2217/fvl-2021-0072. Epub 2021 Jun 30.
2
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.微针阵列递呈的重组冠状病毒疫苗：免疫原性和快速转化开发。
EBioMedicine. 2020 May;55:102743. doi: 10.1016/j.ebiom.2020.102743. Epub 2020 Apr 2.
3
[Vaccination against SARS-CoV-2 in patients with multiple sclerosis].[多发性硬化症患者的新型冠状病毒2型疫苗接种]
Rev Neurol. 2021 Apr 1;72(7):250-260. doi: 10.33588/rn.7207.2021097.
4
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
5
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.CEPI/BC 2020 年 3 月 12-13 日会议共识总结报告：评估 COVID-19 疫苗引起疾病增强的风险。
Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25.
6
How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists.炎症性肠病患者如何应对新冠病毒疫苗接种的到来：胃肠病学家的另一项任务
Vaccines (Basel). 2021 Mar 12;9(3):248. doi: 10.3390/vaccines9030248.
7
Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).2019年冠状病毒病（COVID-19）当前疫苗研发策略综述
Toxicol Pathol. 2020 Oct;48(7):800-809. doi: 10.1177/0192623320959090. Epub 2020 Sep 14.
8
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.新型冠状病毒灭活疫苗在安全性和免疫原性方面的效果：两项随机临床试验的中期分析。
JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543.
9
New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.用于开发 SARS-CoV-2 候选疫苗的新型疫苗生产平台。
Vaccine. 2021 Jan 8;39(2):197-201. doi: 10.1016/j.vaccine.2020.11.054. Epub 2020 Nov 24.
10
COVID Arm: Delayed Hypersensitivity Reactions to SARS-CoV-2 Vaccines Misdiagnosed as Cellulitis.COVID 臂：对 SARS-CoV-2 疫苗的延迟超敏反应被误诊为蜂窝织炎。
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211024431. doi: 10.1177/21501327211024431.
引用本文的文献
1
Factors Influencing COVID-19 Vaccine Hesitancy among Patients with Serious Chronic Illnesses during the Initial Australian Vaccine Rollout: A Multi-Centre Qualitative Analysis Using the Health Belief Model.澳大利亚疫苗首次推广期间影响重症慢性病患者对新冠疫苗犹豫态度的因素：基于健康信念模型的多中心定性分析
Vaccines (Basel). 2023 Jan 20;11(2):239. doi: 10.3390/vaccines11020239.
2
Immune Response to COVID-19 Vaccination in Hematologic Malignancies: A Mini-Review.血液系统恶性肿瘤患者对新冠疫苗接种的免疫反应：一篇综述
Chonnam Med J. 2023 Jan;59(1):24-30. doi: 10.4068/cmj.2023.59.1.24. Epub 2023 Jan 25.
3
Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study.辉瑞-生物科技公司新冠疫苗在妇科肿瘤患者中的应用：一项前瞻性队列研究
Vaccines (Basel). 2021 Dec 23;10(1):12. doi: 10.3390/vaccines10010012.
本文引用的文献
1
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.癌症患者接种一剂与两剂新冠疫苗BNT162b2的安全性和免疫原性：一项前瞻性观察研究的中期分析
Lancet Oncol. 2021 Jun;22(6):765-778. doi: 10.1016/S1470-2045(21)00213-8. Epub 2021 Apr 27.
2
The anti-vaccination infodemic on social media: A behavioral analysis.社交媒体上的反疫苗信息疫情：行为分析。
PLoS One. 2021 Mar 3;16(3):e0247642. doi: 10.1371/journal.pone.0247642. eCollection 2021.
3
High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries.新冠疫苗犹豫率高及其与阴谋论的关联：在约旦、科威特及其他阿拉伯国家开展的一项研究
Vaccines (Basel). 2021 Jan 12;9(1):42. doi: 10.3390/vaccines9010042.
4
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.Ad26.COV2.S 新冠疫苗 1/2a 期临床试验的中期结果。
N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.
5
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
6
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
7
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
8
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).实体瘤癌症患者 2019 年冠状病毒病（COVID-19）严重程度和死亡率的危险因素以及该疾病对癌症治疗的影响：一项法国全国性队列研究（GCO-002 CACOVID-19）。
Eur J Cancer. 2020 Dec;141:62-81. doi: 10.1016/j.ejca.2020.09.035. Epub 2020 Oct 8.
9
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
10
Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China.中国新冠疫情期间新冠疫苗的接种情况
Vaccines (Basel). 2020 Aug 27;8(3):482. doi: 10.3390/vaccines8030482.
Zotero 插件